- Presentations
- 2
- Markets
- 1
Imjudo is a brand of Tremelimumab marketed by AstraZeneca Pharmaceuticals, with 2 presentations listed and registered in United States. Each presentation below has its own page with packs, documents and availability for export supply from India.
- Active ingredient (INN)
- Tremelimumab
- Brand owner
- AstraZeneca Pharmaceuticals
- Registered in
- United States
- Strengths and forms
- 25 mg/1.25 mL injection, 300 mg/15 mL injection
All presentations
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Imjudo 25 mg/1.25 mL injectionIntravenous Cold chain | AstraZeneca Pharmaceuticals | US FDA | Available on request |
| Imjudo 300 mg/15 mL injectionIntravenous Cold chain | AstraZeneca Pharmaceuticals | US FDA | Available on request |
Brand names and trademarks belong to their owners and are used only to identify products.
Request Imjudo
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.